Mobile

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Update Il y a 4 ans
Reference: NCT02582749

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.

Inclusion criteria

  • Prostate cancer,Bone metastases,Prostate Neoplasms

Links